National Oxygen Board Approves 9.50 Lakh Equity Shares Preferential Issue

National oxygen Limited's board of directors has approved the preferential allotment of up to 9.50 lakh equity shares to promoter group company Saraf Housing Development Private Limited. The board meeting, held on March 20, 2026, concluded the fundraising proposal that was initially scheduled for consideration.

Board Meeting Outcome

The board meeting, which commenced at 4:00 PM and concluded at 4:30 PM on March 20, 2026, resulted in the approval of several key resolutions related to the equity fundraising initiative.

Parameter: Details Approved Share Issue: Up to 9.50 lakh equity shares Face Value: Rs. 10.00 per share Allottee: Saraf Housing Development Private Limited Issue Method: Preferential allotment Regulatory Compliance: SEBI ICDR Regulations, 2018

Key Appointments and Approvals

The board appointed CA S Dehaleesan as the registered valuer for determining the issue price of the preferential allotment. CA Dehaleesan holds the registered valuer number IBBI/RV/04/2019/11659 and will be responsible for price determination in accordance with SEBI regulations.

Additionally, the board approved the opening of a separate bank account specifically for the preferential issue process, ensuring proper segregation of funds and compliance with regulatory requirements.

Regulatory Framework and Compliance

The approved equity issue will be conducted under the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, and the Companies Act, 2013. The issue price will be determined at not less than the price calculated in accordance with SEBI ICDR Regulations.

Saraf Housing Development Private Limited, being part of the promoter group, will be the sole recipient of the preferential allotment. The company has made the necessary disclosures under Regulation 30 of SEBI Listing Regulations and SEBI Circular dated July 13, 2023.

Company Operations

National Oxygen Limited operates as an ISO 9001:2015 certified manufacturer specializing in industrial and medical gases. The Chennai-based company manufactures liquid and gaseous oxygen, nitrogen, nitrous oxide, medical oxygen, and dissolved acetylene gas. With manufacturing facilities across Tamil Nadu and Puducherry, the company serves various industrial sectors under its tagline "Breathing Life Into Industry."

National Oxygen Limited has scheduled a board meeting for Friday, January 30, 2026, to review and approve its unaudited financial results for the third quarter of fiscal year 2026. The announcement was made through a formal communication to BSE Limited on January 27, 2026, in compliance with regulatory requirements.

Meeting Details and Regulatory Compliance

The board meeting has been convened in accordance with Regulation 29 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The primary agenda item focuses on the consideration and approval of the company's unaudited financial results for the quarter ended December 31, 2025.

Meeting Parameter: Details Date: Friday, January 30, 2026 Primary Agenda: Unaudited Financial Results for Q3FY26 Quarter Ended: December 31, 2025 Regulatory Framework: SEBI Regulations 29 and 33

Trading Window Restrictions

National Oxygen Limited has implemented trading window restrictions as part of its insider trading prevention measures. The company referenced its earlier communication dated December 25, 2025, which outlined the trading window closure protocol.

The trading restrictions are structured as follows:

Closure Start Date: January 1, 2026

Applicable Persons: Individuals specified under the company's Code of Conduct

Closure Duration: Until 48 hours after the board meeting conclusion

Regulatory Basis: SEBI (Prohibition of Insider Trading) Regulations, 2015

Company Background

National Oxygen Limited operates as an ISO 9001:2015 certified company specializing in the manufacturing of industrial and medical gases. The company's product portfolio includes liquid and gaseous oxygen, liquid and gaseous nitrogen, liquid and gaseous medical oxygen, and dissolved acetylene gas.

The company maintains its registered office in Chennai and operates three manufacturing facilities across Tamil Nadu and Puducherry, supporting its tagline "Breathing Life Into Industry."

Regulatory Communication

The formal notification was signed by Rajesh Kumar Saraf, Managing Director (DIN: 00007353), and submitted to BSE Limited under scrip code 507813. The communication ensures transparency and compliance with stock exchange listing requirements for the upcoming financial results disclosure.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.